Company Summary - Reliance GeneMedix PLC (LSE:GMX)
2.00p
0.25p
(12.50%)
Pharmaceuticals & BiotechnologyMarket cap: £3.810m
NEW Explore our new and improved report for Reliance GeneMedix PLC >>
Gain access to various premium features such as detailed information on financial reports, broker forecasts, directors and shareholders information.
Summary
Development and manufacture of biopharmaceuticals, including biosimilars
| Financials - Interim (16/12/2011) | ||
|---|---|---|
| Turnover | £m | 0.16 |
| Pre-tax Profit | £m | -1.22 |
| EPS | p | -0.60 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Dr. Ramesh Mashelkar | Chairman |
| Vinay Ranade | Chief Executive |
Products Brands & Subsidiaries
Products & Brands
There are no products for this company.
Subsidiaries
BioMetrix Marketing Private Ltd
Broker Sentiment (0 brokers)
No current consensus recommendation available.
| Heading | Date |
|---|---|
| 2011 Interim Results | 16/12/2011 |
| Result of AGM | 28/09/2011 |
| Final Results | 01/09/2011 |